Science & Technology: Receptor-Associated Protein (RAP) and Mesoderm Development Protein (Mesd) Drug-targeting Platforms
We are developing drug-targeting platforms based on the proprietary use of the human protein called receptor-associated protein (RAP) and the mesoderm development protein (Mesd). We believe that these proteins may have therapeutic applications in cancer, infectious diseases and neurodegenerative diseases, among others.
These applications are based on the assumption that our targeting molecules can be engineered to bind to a selective subset of receptors with restricted tissue distribution under particular conditions of administration. We believe these selective tissue distributions can be used to deliver drugs to the liver or to other tissues, such as the brain.
In addition to selectively transporting drugs to specific tissues, selective receptor binding constitutes a means by which receptor function might be specifically controlled, either through modulating its binding capacity or its prevalence on the cell surface. Mesd is being engineered for this latter application.
Raptor's Receptor-Associated Protein (RAP) Drug-targeting Platform
- HepTide™ for the potential treatment of primary liver cancer and hepatitis C
- NeuroTrans™ for the potential delivery of therapeutics across the blood-brain barrier
Raptor's Mesoderm Development Protein (Mesd) Platform
- WntTide™for the potential treatment of breast cancer